Healthcare Equipment and Supplies
Company Overview of Amedica Corporation
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices in the United States. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; Valeo stand-alone anterior lumbar intervertebral fusion device; and a line of non-silicon nitride spinal fusion products used by surgeons to promote bone growth and fusion in spinal fusion procedures. The company also develops femoral heads for use in its total hip replacements; and femoral condyle components for use in its total knee replacements. It markets and sells its products to surgeons and hospitals in the United State...
1885 West 2100 South
Salt Lake City, UT 84119
Founded in 1996
Key Executives for Amedica Corporation
Chief Technology Officer
Total Annual Compensation: $228.5K
Compensation as of Fiscal Year 2013.
Amedica Corporation Key Developments
Amedica Announces Receipt Of Nasdaq Notice Of Bid Price Deficiency
Feb 20 15
Amedica Corporation announced that on February 19, 2015, the Company received a letter from the Nasdaq Listings Qualifications department of the Nasdaq Capital Market ("Nasdaq") notifying the Company that the minimum bid price per share for its common stock was below $1.00 for a period of thirty (30) consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under the symbol "AMDA." Amedica management intends to resolve the situation to allow for continued listing on the Nasdaq Capital Market. The Company has a compliance period of 180 calendar days, or until August 18, 2015, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the 180-day compliance period, the closing bid price per share of the Company's common stock is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with Rule 5550(a)(2) within this compliance period, it may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials or make the required representations, the Company's common stock will be subject to delisting by Nasdaq.
Amedica Corporation Files Submission for 510(K) Clearance of Valeo C Interbody with CsC Osteo-Conductive Scaffolding with U.S. Food and Drug Administration
Feb 12 15
Amedica Corporation announced that it has filed a submission for 510(k) clearance of the Valeo C Interbody with CsC Osteo-Conductive Scaffolding (Valeo C) with the U.S. Food and Drug Administration (FDA) relating to its composite silicon nitride spinal interbody devices.
Amedica Corporation to Receive U.S. Food and Drug Administration Clearance for Two-Level Cervical Interbody Cage Indications
Feb 3 15
Amedica Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the indications of Amedica's silicon nitride interbody fusion products to include multi-level cervical treatment. The FDA's clearance of the expanded indications is based on extensive data from a variety of studies and sources showing the Company's silicon nitride devices used in multi-level procedures are as safe and effective as other devices used in single level procedures. The Valeo™ cervical fusion devices are now indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels. The FDA approval order allows for commercial sales and distribution of these devices for multi-level procedures.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 30, 2014
Most Searched Private Companies
Sponsored Financial Commentaries